Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sagun Parakh, Joseph Nicolazzo, Andrew M Scott, Hui Kong Gan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	antibody drug conjugates (ADC) glioma glioblastoma blood brain barrier tumour microenvironment biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/75bd5259ae494948a7493d5c5e2d644f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75bd5259ae494948a7493d5c5e2d644f
record_format	dspace
spelling	oai:doaj.org-article:75bd5259ae494948a7493d5c5e2d644f2021-12-03T06:13:33ZAntibody Drug Conjugates in Glioblastoma – Is There a Future for Them?2234-943X10.3389/fonc.2021.718590https://doaj.org/article/75bd5259ae494948a7493d5c5e2d644f2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.718590/fullhttps://doaj.org/toc/2234-943XGlioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrated superior efficacy and/or reduced toxicity in a range of haematological and solid tumors resulting in nine ADCs receiving regulatory approval. ADCs have also been explored in patients with brain tumours but with limited success to date. While earlier generations ADCs in glioma patients have had limited success and high toxicity, newer and improved ADCs characterised by low immunogenicity and more effective payloads have shown promise in a range of tumour types. These newer ADCs have also been tested in glioma patients, however, with mixed results. Factors affecting the effectiveness of ADCs to target the CNS include the blood brain barrier which acts as a physical and biochemical barrier, the pro-cancerogenic and immunosuppressive tumor microenvironment and tumour characteristics like tumour volume and antigen expression. In this paper we review the data regarding the ongoing the development of ADCs in glioma patients as well as potential strategies to overcome these barriers to maximise their therapeutic potential.Sagun ParakhSagun ParakhSagun ParakhJoseph NicolazzoAndrew M ScottAndrew M ScottAndrew M ScottAndrew M ScottHui Kong GanHui Kong GanHui Kong GanHui Kong GanFrontiers Media S.A.articleantibody drug conjugates (ADC)gliomaglioblastomablood brain barriertumour microenvironmentbiomarkersNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antibody drug conjugates (ADC) glioma glioblastoma blood brain barrier tumour microenvironment biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	antibody drug conjugates (ADC) glioma glioblastoma blood brain barrier tumour microenvironment biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sagun Parakh Sagun Parakh Sagun Parakh Joseph Nicolazzo Andrew M Scott Andrew M Scott Andrew M Scott Andrew M Scott Hui Kong Gan Hui Kong Gan Hui Kong Gan Hui Kong Gan Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
description	Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrated superior efficacy and/or reduced toxicity in a range of haematological and solid tumors resulting in nine ADCs receiving regulatory approval. ADCs have also been explored in patients with brain tumours but with limited success to date. While earlier generations ADCs in glioma patients have had limited success and high toxicity, newer and improved ADCs characterised by low immunogenicity and more effective payloads have shown promise in a range of tumour types. These newer ADCs have also been tested in glioma patients, however, with mixed results. Factors affecting the effectiveness of ADCs to target the CNS include the blood brain barrier which acts as a physical and biochemical barrier, the pro-cancerogenic and immunosuppressive tumor microenvironment and tumour characteristics like tumour volume and antigen expression. In this paper we review the data regarding the ongoing the development of ADCs in glioma patients as well as potential strategies to overcome these barriers to maximise their therapeutic potential.
format	article
author	Sagun Parakh Sagun Parakh Sagun Parakh Joseph Nicolazzo Andrew M Scott Andrew M Scott Andrew M Scott Andrew M Scott Hui Kong Gan Hui Kong Gan Hui Kong Gan Hui Kong Gan
author_facet	Sagun Parakh Sagun Parakh Sagun Parakh Joseph Nicolazzo Andrew M Scott Andrew M Scott Andrew M Scott Andrew M Scott Hui Kong Gan Hui Kong Gan Hui Kong Gan Hui Kong Gan
author_sort	Sagun Parakh
title	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
title_short	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
title_full	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
title_fullStr	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
title_full_unstemmed	Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
title_sort	antibody drug conjugates in glioblastoma – is there a future for them?
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/75bd5259ae494948a7493d5c5e2d644f
work_keys_str_mv	AT sagunparakh antibodydrugconjugatesinglioblastomaisthereafutureforthem AT sagunparakh antibodydrugconjugatesinglioblastomaisthereafutureforthem AT sagunparakh antibodydrugconjugatesinglioblastomaisthereafutureforthem AT josephnicolazzo antibodydrugconjugatesinglioblastomaisthereafutureforthem AT andrewmscott antibodydrugconjugatesinglioblastomaisthereafutureforthem AT andrewmscott antibodydrugconjugatesinglioblastomaisthereafutureforthem AT andrewmscott antibodydrugconjugatesinglioblastomaisthereafutureforthem AT andrewmscott antibodydrugconjugatesinglioblastomaisthereafutureforthem AT huikonggan antibodydrugconjugatesinglioblastomaisthereafutureforthem AT huikonggan antibodydrugconjugatesinglioblastomaisthereafutureforthem AT huikonggan antibodydrugconjugatesinglioblastomaisthereafutureforthem AT huikonggan antibodydrugconjugatesinglioblastomaisthereafutureforthem
_version_	1718373878464512000

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Ejemplares similares